Literature DB >> 26574671

Clinical Outcome of Silent Subtype III Pituitary Adenomas Diagnosed by Immunohistochemistry.

Timothy E Richardson1, Derek A Mathis, Bruce E Mickey, Jack M Raisanen, Dennis K Burns, Charles L White, Kimmo J Hatanpaa.   

Abstract

Silent subtype III pituitary adenomas (SS-3) are nonfunctioning radiosensitive adenomas that may be associated with an increased risk of recurrence and invasion. The features that have been proposed to be diagnostically important are identifiable by electron microscopy (EM) and include an enlarged Golgi apparatus, along with several other ultrastructural features. The often limited availability of EM and the uncertainty about the relative importance of individual features pose practical challenges to the diagnosis. We hypothesized that it may be possible to diagnose SS-3 based solely on a markedly enlarged Golgi apparatus identified at the light microscopic level. In this prospective study, we used immunohistochemistry (IHC) for the Golgi apparatus with the MG-160/GLG-1 antibody to identify 10 cases with features suggestive of SS-3. Electron microscopy was performed for confirmation on 1 case. Compared with a control group of 20 conventional null cell adenomas, the SS-3 adenomas showed an increased MIB-1 proliferation index (p < 0.01), a higher risk of invasion (p < 0.01), and a higher incidence of recurrence (p < 0.01). Thus, in this first controlled study, we demonstrate that SS-3 is clinically aggressive and identifiable by IHC, without the need for EM. The routine diagnostic workup of nonsecreting adenomas should rule out SS-3, which can be done quickly and efficiently by IHC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26574671     DOI: 10.1097/NEN.0000000000000265

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  5 in total

1.  Growth hormone-producing pituitary adenomas in childhood and young adulthood: clinical features and outcomes.

Authors:  Yuichi Nagata; Naoko Inoshita; Noriaki Fukuhara; Mitsuo Yamaguchi-Okada; Hiroshi Nishioka; Takeo Iwata; Katsuhiko Yoshimoto; Shozo Yamada
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

2.  Plurihormonal PIT-1-Positive Pituitary Adenomas: A Systematic Review and Single-Center Series.

Authors:  John P Andrews; Rushikesh S Joshi; Matheus P Pereira; Taemin Oh; Alexander F Haddad; Kaitlyn M Pereira; Robert C Osorio; Kevin C Donohue; Zain Peeran; Sweta Sudhir; Saket Jain; Angad Beniwal; Ashley S Chopra; Narpal S Sandhu; Tarik Tihan; Lewis Blevins; Manish K Aghi
Journal:  World Neurosurg       Date:  2021-04-20       Impact factor: 2.210

3.  Is it time to consider the expression of specific-pituitary hormone genes when typifying pituitary tumours?

Authors:  Araceli García-Martínez; Johana Sottile; Carmen Fajardo; Pedro Riesgo; Rosa Cámara; Juan Antonio Simal; Cristina Lamas; Hernán Sandoval; Ignacio Aranda; Antonio Picó
Journal:  PLoS One       Date:  2018-07-06       Impact factor: 3.240

Review 4.  Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor.

Authors:  Peiqiong Luo; Lin Zhang; Lidan Yang; Zhenmei An; Huiwen Tan
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-27       Impact factor: 5.555

5.  A pathogenic UFSP2 variant in an autosomal recessive form of pediatric neurodevelopmental anomalies and epilepsy.

Authors:  Min Ni; Bushra Afroze; Chao Xing; Chunxiao Pan; Yanqiu Shao; Ling Cai; Brandi L Cantarel; Jimin Pei; Nick V Grishin; Stacy Hewson; Devon Knight; Sonal Mahida; Donnice Michel; Mark Tarnopolsky; Annapurna Poduri; Alexander Rotenberg; Neal Sondheimer; Ralph J DeBerardinis
Journal:  Genet Med       Date:  2021-01-20       Impact factor: 8.822

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.